Guardant Health (GH) Stock Outlook 2026: Betting on the Liquid Biopsy Screening Wave
Guardant Health (Nasdaq: GH) Stock Outlook 2026: how this liquid biopsy leader is building from therapy selection into the huge colorectal cancer screening market, the Guardant360, Reveal, and Shield pipeline, the screening TAM, reimbursement and guideline catalysts, fast revenue growth versus losses and cash burn, competition from Exact Sciences and Natera, and the risks to watch.